TY - JOUR T1 - Follow-up study on serum cholesterol profiles in recovered COVID-19 patients JF - medRxiv DO - 10.1101/2020.12.08.20245977 SP - 2020.12.08.20245977 AU - Guiling Li AU - Li Du AU - Xiaoling Cao AU - Xiuqi Wei AU - Yao Jiang AU - Yuqi Lin AU - Vi Nguyen AU - Wenbin Tan AU - Hui Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/11/2020.12.08.20245977.abstract N2 - COVID-19 patients develop hypolipidemia. However, it is unknown whether lipid levels have improved in recovered patients. In this study, a 3–6 month follow-up study was performed to examine serum levels of laboratory values in 107 discharged COVID-19 patients (mild = 59; severe/critical = 48; diagnoses on admission). 61 patients had a revisit chest CT scan. A Wilcoxon signed-rank test was used to analyze changes in laboratory values. LDL-c and HDL-c levels were significantly higher at follow-up than at admission in severe/critical cases (p < 0.05). LDL-c levels were significantly higher at follow-up than at admission in mild cases (p < 0.05). With adjustment of the factor of traditional Chinese medicine, LDL-c and HDL-c levels were significantly improved at follow-up than at admission in severe/critical cases (p < 0.05). Increases in HDL-c significantly correlated with increases in numbers of white blood cells (p<0.001) and decreases in levels of C-reactive protein (p < 0.05) during patients’ recovery. Residue lesions were observed in CT images in 69% (42 of 61) of follow-up patients. We concluded that improvements of LDL-c, HDL-c and incomplete absorption of lung lesions were observed at follow-up for recovered patients, indicating that a long-term recovery process could be required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Health and Family Planning Commission of Hubei Province (Grant No. WJ2019M158 to HW).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board (IRB) at the Union Hospital. Oral consent was obtained from the participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe collection of data that supports the findings in this study is available from the Union Hospital, Wuhan, but restrictions may apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Union Hospital, Wuhan. ER -